Recurrent respiratory papillomatosis: an overview of current thinking and treatment

Goon, Peter; Sonnex, C; Jani, Piyush; Stanley, Margaret; Sudhoff, Holger

doi:10.1007/s00405-007-0546-z

Cited by 133 publications

(136 citation statements)

References 46 publications

(47 reference statements)

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Therefore such precise quantitative comparison was not possible in our study. The overall HPV genotype prevalence in our study group was consistent with data published earlier, demonstrating that HPV6 and HPV11 are the dominant types in JORRP patients (12,16,20); however, in our study more cases of HPV11-related papillomas were observed (70%), whereas it was previously reported that the predominant genotype in JORRP patients was HPV6 (19). This may be due to the particular HPV epidemiology seen in our Polish population.…”

supporting

confidence: 91%

Detection of Anti-HPV11-L1 Antibodies in Immune Sera from Patients Suffering from Recurrent Respiratory Papillomatosis Using ELISA

Durzyńska

Błażejewska

Szydłowski³

et al. 2010

Viral Immunology

View full text Add to dashboard Cite

CitationDetection of anti-HPV11-L1 antibodies in immune sera from patients suffering from recurrent respiratory papillomatosis using ELISA. Infection with human papillomaviruses (mostly HPV6 and HPV11) may lead to recurrent respiratory papillomatosis (RRP), a chronic disease affecting 2-4/100,000 people. Papillomas have to be removed surgically so patients can breathe normally. Papillomas often grow back and some patients are subjected to a number of operations. In general, asymptomatic HPV-positive people have low levels of antiviral antibodies in their sera, as the human humoral response is weak due to HPV's biology. In patients suffering from RRP who have undergone multiple surgeries, a blood-epithelium barrier breach stimulates the production of anti-HPV antibodies. Our study's aim was to produce HisTag-HPV11-L1 major capsid protein in E. coli cells, and to purify it. We also sought to detect anti-HPV11-L1 antibodies in antisera obtained from RRP patients using ELISA. Clinical samples were collected from 47 patients with RRP (antisera and papillomas), and from 32 controls (sera and oral swabs), from the Wielkopolska region of Poland. Antisera and control sera were used to coat microplates, HisTag-HPV11-L1 antigen was applied, and antibody-antigen complexes were detected by anti-HisTag monoclonal antibody in an ELISA assay. Simultaneously, total cellular DNA was extracted from papillomas and oral squamous cells obtained from controls. All DNA samples were screened for HPV DNA using MY-PCR. All patients were HPV-positive (30% for HPV6 and 70% for HPV11). Statistically significant correlations were found between the amount of anti-HPV11-L1 antibodies in the sera of RRP patients and the number of surgical procedures they underwent. Although HPV virus-like particles are most often used for anti-HPV antibody detection, the ELISA method presented herein is another viable option for use in RRP patients.

show abstract

supporting

confidence: 91%

Detection of Anti-HPV11-L1 Antibodies in Immune Sera from Patients Suffering from Recurrent Respiratory Papillomatosis Using ELISA

Durzyńska

Błażejewska

Szydłowski³

et al. 2010

Viral Immunology

View full text Add to dashboard Cite

show abstract

“…The human papillomavirus (HPV) is the aetiological cause of several benign and malignant tumors 1, 2, 3. Although recurrent respiratory papillomatosis (RRP) is a rare disease, there is severe morbidity and occasional mortality.…”

Section: Introductionmentioning

confidence: 99%

“…Although recurrent respiratory papillomatosis (RRP) is a rare disease, there is severe morbidity and occasional mortality. The incidence of this terrible disease is low (approximately 4/100,000 live births) but this background risk rises dramatically to 1/400 in women who have detectable wart infection during pregnancy 3. RRP can be divided into adult and juvenile forms.…”

Section: Introductionmentioning

confidence: 99%

Recurrent respiratory papillomatosis (RRP)–time for a reckoning?

Goon

Scholtz²,

Sudhoff³

2017

Laryngoscope Investig Oto

Self Cite

View full text Add to dashboard Cite

ObjectivesRecurrent respiratory papillomatosis (RRP) is a rare disease, but one with severe morbidity and occasional mortality. The aetiological agent is human papillomavirus (HPV), and HPV types 6 and 11 account for over 90% of all cases. In the active phase of the disease, patients require multiple hospital admissions for surgical removal or ablation of these benign tumors, which are likely to obstruct the airways if left unchecked. Long‐term sequelae include scarring of the vocal cords, change in voice timbre, or even muteness if a tracheostomy is required. The aim of this study was to determine if adjuvant vaccination with the quadrivalent HPV L1 vaccine (Gardasil™) would decrease numbers of surgical treatments post‐vaccination.MethodsA prospective pilot study following a cohort of 12 RRP patients, all of whom gave fully informed consent to participate. All patients had their papillomas typed and if they were found to have types 6 or 11, were vaccinated at the time of first surgical treatment in the hospital, according to the manufacturer's protocols. Patients were followed up closely with 3 or 6 month follow‐up visits. Standard surgical treatments were given and were not affected by whether they participated in the study.ResultsWe found a >7‐fold decrease in the incidence rates of papillomatosis requiring surgical intervention from the pre‐vaccination period (47.44/1000 patient‐months) compared to the post‐vaccination period (6.71/1000 patient‐months).DiscussionSurgical treatments for RRP are robust markers for papillomata which require treatment because of the dangers of obstruction of the airway. Despite the small size of this cohort (due to the rarity of this disease), the data suggests that adjuvant use of quadrivalent HPV L1 vaccine imparts significant benefit to this group of patients. A large multi‐center randomized placebo controlled trial is required to definitively establish whether this hypothesis is true and can become the new standard of therapy.Level of Evidence3b

show abstract

“…RRP, known as laryngeal papillomatosis, is a common benign tumor of the airways (Derkay, 2001) characterized by exophytic proliferative lesions of connective tissue. In most cases, this condition is spontaneously resolved with less than 1% progressing to malignancy (Goon et al, 2008). The papillomas can grow anywhere in the respiratory tract such as trachea, bronchi and lung but most commonly in the larynx (Lacey et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

Whole Genome Analysis of Human Papillomavirus Genotype 11 from Cervix, Larynx and Lung

Chansaenroj

Theamboonlers²,

Junyangdikul³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The prevalence of human papillomavirus genotypes differs in various target organs. HPV16 is the most prevalent genotype in the cervix while genotypes 6 and 11 are highly prevalent in skin and aero-digestive tract infections. In this study HPV11 positive specimens were selected from cervix, larynx and lung biopsy tissue to analyze the whole genome by PCR and direct sequencing. Five HPV11 whole genomes were characterized, consisting of two cervical specimens, two laryngeal specimens and one lung specimen. The results showed high homology of HPV11 in these organs. Phylogenetic analysis showed that all HPV11 derived from various organs belonged to the same lineage. Molecular characterization and functional studies can further our understanding of virulence, expression or transmission. Additional studies on functional protein expression at different organ sites will also contribute to our knowledge of HPV infection in various organs.

show abstract

Recurrent respiratory papillomatosis: an overview of current thinking and treatment

Cited by 133 publications

References 46 publications

Detection of Anti-HPV11-L1 Antibodies in Immune Sera from Patients Suffering from Recurrent Respiratory Papillomatosis Using ELISA

Detection of Anti-HPV11-L1 Antibodies in Immune Sera from Patients Suffering from Recurrent Respiratory Papillomatosis Using ELISA

Recurrent respiratory papillomatosis (RRP)–time for a reckoning?

Whole Genome Analysis of Human Papillomavirus Genotype 11 from Cervix, Larynx and Lung

Contact Info

Product

Resources

About